Lori J. Wirth
Distinguished in Teratocarcinosarcoma

Dr. Lori J. Wirth

Oncology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Distinguished in Teratocarcinosarcoma
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lori Wirth is an Oncologist in Boston, Massachusetts. Dr. Wirth is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Thyroid Cancer, Medullary Thyroid Carcinoma, Papillary Thyroid Cancer, Tissue Biopsy, and Thyroidectomy. Dr. Wirth is currently accepting new patients.

Her clinical research consists of co-authoring 157 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
North Shore Medical Center -
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114
Other Locations
THE GENERAL HOSPITAL CORPORATION
102 Endicott St, Danvers, MA 01923

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
A Phase IB Rescue Study With Oral Decitabine (AStX727) and Durvalumab (MEDI4736) Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drugs: Decitabine, Durvalumab
Study Phase: Phase 1
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Selumetinib, Iodine-131
Study Phase: Phase 2
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Enrollment Status: Completed
Publish Date: June 28, 2023
Intervention Type: Drug, Biological
Study Drugs: Autologous Epstein Barr Virus-Specific Cytotoxic T Cells, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Enrollment Status: Completed
Publish Date: October 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Biological
Study Phase: Phase 1
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center
Enrollment Status: Completed
Publish Date: May 25, 2017
Intervention Type: Other
Study Phase: Not Applicable
View 10 Less Clinical Trials

157 Total Publications

Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review.
Emerging EGFR-Targeted Therapy in Head and Neck Cancer: A Review.
Journal: JAMA oncology
Published: September 25, 2025
Similar Doctors
Distinguished in Teratocarcinosarcoma
Dr. Jong C. Park
Hematology Oncology | Oncology | Hematology
Distinguished in Teratocarcinosarcoma
Dr. Jong C. Park
Hematology Oncology | Oncology | Hematology

Massachusetts General Physicians Organization Inc

243 Charles St, Suite 1107, 
Boston, MA 
 (0.1 miles away)
617-273-5699
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jong Park is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Sinus Cancer, Olfactory Neuroblastoma, Teratocarcinosarcoma, Nasopharyngeal Carcinoma, and Tissue Biopsy. Dr. Park is currently accepting new patients.

Robert I. Haddad
Distinguished in Teratocarcinosarcoma
Dr. Robert I. Haddad
Oncology
Distinguished in Teratocarcinosarcoma
Dr. Robert I. Haddad
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Haddad is an Oncologist in Boston, Massachusetts. Dr. Haddad is rated as an Elite provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Anaplastic Thyroid Cancer, Adenoid Cystic Carcinoma, Laryngeal Cancer, and Thyroidectomy. Dr. Haddad is currently accepting new patients.

Distinguished in Teratocarcinosarcoma
Dr. John R. Clark
Hematology Oncology | Oncology
Distinguished in Teratocarcinosarcoma
Dr. John R. Clark
Hematology Oncology | Oncology
55 Fruit Street, Yaw 7b Mass General Hospital, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances

John Clark is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Clark is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Nasopharyngeal Carcinoma, Laryngeal Cancer, Tongue Cancer, Teratocarcinosarcoma, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wirth's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 9 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile